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Abstract Urocortin (UCN) is a 40-amino-acid peptide and
a member of the corticotropin-releasing hormone (CRH)
family, which includes CRH, urotensin I, sauvagine,
UCN2 and UCN3. The biological actions of CRH family
peptides are mediated via two types of G-protein-coupled
receptors, namely CRH type 1 receptor (CRHR1) and CRH
type 2 receptor (CRHR2). The biological effects of these
peptides are mediated and modulated not only by CRH
receptors but also via a highly conserved CRH-binding
protein (CRHBP). Our aim was to investigate the expression
of UCN, CRHR1, CRHR2 and CRHBP by immunohisto-
chemistry, Western blot and reverse transcription with the
polymerase chain reaction (RT-PCR) in the horse thyroid
gland. The results showed that UCN, CRHR1 and CRHR2
were expressed in the thyroid gland, whereas CRHBP was
not expressed. Specifically, UCN immunoreactivity (-IR)
was found in the thyroid follicular cells, CRHR2-IR in the
C-cells and CRHR1-IR in blood vessels. Western blot anal-
ysis and RT-PCR experiments confirmed the immunohisto-
chemical data. These results suggest that a regulatory
system exists in the mammalian thyroid gland based on
UCN, CRHR1 and CRHR2 and that UCN plays a role in
the regulation of thyroid physiological functions through a
paracrine mechanism.
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Introduction
Urocortin (UCN) is a peptide of 40 amino acids and is a
member of the corticotropin-releasing hormone (CRH) fam-
ily, which includes CRH, urotensin I, sauvagine, UCN2 and
UCN3. Vaughan et al. (1995) were the first to identify UCN,
which exhibits 45% homology to CRH (Latchman 2002;
Donaldson et al. 1996; Fekete and Zorrilla 2007). Like
CRH, UCN can stimulate adrenocorticotrophic hormone
(ACTH) production from anterior pituitary corticotrophs in
vitro and in vivo (Asaba et al. 1998).
UCN is more potent than CRH with regard to other
biological effects, including the suppression of appetite but
is less potent in generating anxiety. A few years after the
identification of UCN, two additional mammalian CRH-like
peptides were isolated. UCN2 (stresscopin-related peptide)
is a 38-amino-acid peptide with an amidated C-terminus and
was first predicted in mouse from a gene encoding a 112-
amino-acid protein (Reyes et al. 2001; Hsu and Hsueh 2001;
Yamauchi et al. 2005). Human UCN3 (stresscopin) was
identified later and found to have high identity (>80%) to
UCN2 (Lewis et al. 2001; Takahashi et al. 2004; Saruta et al.
2005; Imperatore et al. 2006). The biological effects of CRH
and UCNs are mediated by two distinct receptors, namely
CRH receptor types 1 (CRHR1) and 2 (CRHR2), which
belong to the G-protein-coupled receptor superfamily of
brain-gut neuropeptides (Perrin et al. 1993; Vita et al.
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1995; Chen et al. 1993; Perrin et al. 2006). Two separate
genes encode the CRH receptors (Chen et al. 1993).
CRHR1, a 415-amino-acid protein, exhibits high affinity
towards CRH and UCN but low affinity towards UCN2
and no affinity towards UCN3. CRHR1 is primarily
expressed in the central nervous system (CNS) and the
anterior pituitary. The CRHR2 receptor shares 70% se-
quence identity with CRHR1 and is expressed primarily in
extra-CNS sites. CRHR2 receptors exhibit high affinity to-
wards UCNs and no affinity towards CRH. Activation of
CRHR2 suppresses multiple metabolic functions, including
feeding in fasted mice (Bale et al. 2000), heat-induced oedema
and gastric emptying (Kishimoto et al. 2000).
The biological effects of UCN and other CRH-related
ligands are mediated and controlled not only by CRH recep-
tors but also by the CRH-binding protein (CRHBP). The
CRHBP is a 37-kDa glycoprotein identified not only in
mammals but also in non-mammalian vertebrates including
fishes, amphibians and birds, suggesting that it is a phylo-
genetically ancient protein with extensive structural and
functional conservation (Seasholtz et al. 2002). It was orig-
inally isolated from human plasma (Orth and Mount 1987;
Behan et al. 1989) and then found in several rat brain areas
including the anterior pituitary gland (Potter et al. 1992;
Peto et al. 1999). It is distinct from the CRH receptors and
binds hCRH and UCN with an equal or greater affinity than
the CRH receptors (Sutton et al. 1995; Vaughan et al. 1995).
A major function of CRHBP is to modulate the access of
CRH to CRHRs (Seasholtz et al. 2002).
The expression of UCN and CRHRs is not limited to the
brain, as recent studies have detected immunoreactivity and
mRNA for UCNs and their receptors in the digestive, cardio-
vascular, reproductive, immune and endocrine systems sug-
gesting important roles for these factors throughout the body
(Oki and Sasano 2004; Yang et al. 2010; Venkatasubramanian
et al. 2010; Squillacioti et al. 2011).
Despite this evidence, no indications are available
concerning the expression of CRH-related peptides in the
normal thyroid gland. CRH, UCN 1 and UCN 3, however,
have been found to be expressed in thyroid medullary car-
cinomas (Kageyama et al. 2008). CRH immunoreactivity
(CRH-IR), in addition, has been detected in thyroid autoim-
mune and neoplastic lesions such as Hashimoto thyroiditis,
neoplasms and goiters, suggesting that CRH may be directly
and/or indirectly involved with inflammatory processes tak-
ing place in this gland (Scopa et al. 1994).
The aim of the present study has been to investigate the
expression of UCN, CRHR1, CRHR2 and CRHBP in the
horse thyroid gland to verify the existence of a regulatory
system based on UCN, CRHRs and CRHBP in normal mam-
malian thyroid tissues. For this purpose, we have performed
Western blot and immunohistochemistry to study the presence
and distribution of these proteins and reverse transcription
with the polymerase chain reaction (RT-PCR) to evaluate
mRNA expression in the thyroid gland of the horse.
Materials and methods
Animals and tissue collection
This study was performed on six adult healthy horses of
both sexes coming from the same farm located in southern
Italy. The animals were bred under natural environmental
conditions and were fed hay and concentrate. Water was
available continuously. The animals were killed in a public
slaughterhouse according to current Italian animal care pro-
tocols. Thyroid glands from these animals were collected on
the same day. In adddition, blood serum and fresh segments
of various regions of the brain (i.e. cerebellum, hypothal-
almus, thalamus, cerebral cortex), adenohypophysis and
liver were collected. For Western blot and RT-PCR analyses,
the specimens were immediately frozen on dry ice and
stored at −80°C. For immunohistochemical studies, the
specimens were immediately fixed.
Immunoprecipitation and Western blot analysis
Frozen tissues were homogenised in a homogenisation buffer
(50 mM TRIS-HCl pH 7.0, 150 mM NaCl, 2 % Triton, 5 mM
EDTA, 10 mg/ml leupeptin, 0.1 U/ml aprotinin, 1 mM phenyl-
methane sulfonyl-fluoride) by using an Ultra-Turrax homoge-
niser and centrifuged at 16,000g for 20 min at 4°C. The
resulting supernatants were characterised for protein concen-
tration by Bio-Rad protein assay. Equal amounts of proteins
were immunoprecipitated overnight at 4°C with anti-UCN, -
CRHR1 and –CRH2 (1 μg antibody/200 μg protein) previous-
ly bound to protein A/G-Agarose. A fraction of supernatant was
used as an immunoprecipitation input control (as a loading
control). Beads were sedimented by brief centrifugation and
washed extensively with an ice-cold homogenisation buffer.
Proteins, solubilised in a boiling sodium dodecyl sulphate
(SDS) sample buffer (2% SDS, 5%L-mercaptoethanol,
66 mM TRIS pH 7.5, 10 mM EDTA), were separated on
18% and 12% SDS-polyacrylamide gels (Bio-Rad, Hercules,
Calif., USA). In addition, aliquots of homogenate were sub-
jected to electrophoresis on a 12% SDS-polyacrylamide gel.
After electrophoresis, the gel was transferred to nitrocellulose
by using a semi-dry apparatus (Bio-Rad) according to the
manufacturer’s instructions. The membrane was incubated for
1 h at 42°C in 5% bovine serum albumin (BSA; Sigma, St.
Louis, Mo., USA) in TBST (150 mMNaCl, 20 mMTRIS-HCl
pH 7.4, 0.3%Tween-20), washedwith TBSTand incubated for
2 h at room temperature in the antisera diluted 1:500 in TBST
containing 1% BSA. The following antisera were used: poly-
clonal goat anti-UCN (sc-1825; Santa Cruz Biotechnology,
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Santa Cruz, Calif., USA), anti-CRHR1 (sc-12383; Santa Cruz
Biotechnology), anti-CRHR2 (sc-1826; Santa Cruz Biotech-
nology), rabbit anti-CRHBP (SAB1300862; Sigma-Aldrich,
St. Louis, Mo., USA) and mouse monoclonal anti-actin
(JLA20 CP01; Calbiochem, San Diego, Calif., USA).
The membrane was washed three times with TBST, in-
cubated for 1 h with anti-goat or anti-rabbit or anti-mouse
IgG peroxidase conjugate (Vector Laboratories, Burlin-
game, Calif., USA) diluted 1:2000 in TBST-1% BSA and
washed three times with TBST. Proteins were visualised by
an enhanced chemiluminescence kit (Amersham, Bucking-
hamshire, UK). Marker proteins (coloured protein molecular
weight markers; Prosieve, Lonza) were used to estimate the
molecular weight of each band.
Immunohistochemistry
Fresh segments of tissues were fixed by immersion in Bouin’s
fixative (6–24 h), processed for paraffin embedding in a vacuum
and cut at a thickness of 3–6 mμ. The avidin–biotin–peroxidase
complex (ABC) method was performed by using the Vectastain
ABC kit (Vector Laboratories) as described more fully else-
where (Squillacioti et al. 2011). Primary antibodies were: poly-
clonal goat anti-UCN (diluted 1:500; sc-1825; Santa Cruz
Biotechnology), anti-CRHR1 (diluted 1:500; sc-12383; Santa
Cruz Biotechnology), anti-CRHR2 (diluted 1:500; sc-1826;
Santa Cruz Biotechnology), rabbit anti-CRHBP (diluted 1:500;
SAB1300862) and goat polyclonal anti-chromogranin A
(diluted 1:1000; sc-1488; Santa Cruz Biotechnology).
The secondary antibodies were: biotinylated anti-goat or
anti-rabbit IgG (diluted 1:200; Vector). The specificity of the
immunoreactions was tested by replacing the primary anti-
body with a buffer. No immunoreaction was detected in
control tests. The specificity of the primary antibodies was
tested by pre-absorption with excess homologous antigen
peptide and by using dot-blot assay as described more fully
elsewhere (Squillacioti et al. 2011). The slides were observed
by using a Leica DMRA2 microscope (Leica Microsystems,
Wetzlar, Germany).
RNA extraction, cDNA synthesis, RT-PCR and sequencing
Samples of the frozen thyroid tissue were individually
homogenised in ice-cold TRI-Reagent (Sigma) by using an
Ultra-Turrax homogeniser. After chloroform extraction and
isopropyl alcohol precipitation, RNA was dissolved in
RNAase-free diethylpyrocarbonate-containing water. Total
RNA was measured with an Eppendorf Biophotometer
(Eppendorf, Basel, Switzerland). For cDNA synthesis,
1 μg total RNAwas retro-transcribed with the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems, USA)
and random hexamers as primers. For PCRs, specific primers
for Equine UCN, CRH-R1, CRH-R2 and CRHBP were
designed from the published gene sequences (Equus cab-
allus UCN-like mRNA, Genbank accession number
XM_001502361; Equus caballus CRHR1 mRNA, Genbank
accession number XM_001496135, Equus caballus CRHR2
mRNA, Genbank accession number XM_001916709 and
Equus caballus CRHBP mRNA, Genbank accession number
XM_001918250) by using Primer Express software (PE Ap-
plied Biosystems).
The sense and anti-sense UCN primers used were 5’-
CCGAGTCTGCGCTGGATT–3’ and 5’-GTGGAAGGT
GAGGTCAATGGA –3’,respectively, which amplify a 177-
bp fragment. The sense and anti-sense CRH-R1 primers were
5’-TACTACGACAACGAGAAGTGCTGGTT–’ and 5’-
AGCACCAGAGTGGCCTTCAC–3’, respectively, which
amplify a 200-bp fragment. The sense and anti-sense CRHR2
primers were 5’-ACGAAGTGCACGAGAGCAAC–3’ and
5’-CCAGCACTGTTCGTTC–3’, respectively, which ampli-
fy a 230-bp fragment. The sense and anti-sense CRHBP
primers were 5’-CAGACCCCAAACGGAAGGTT-3’ and
5’-CAGGGCCACGAAAGGGATA-3’ respectively, which
amplify a 250-bp fragment. In order to verify the efficiency
of the RT and to exclude genomic DNA contamination, a
fragment of β-actin cDNA (GenBank accession number
NC_009156) was amplified and sequenced with primers
designed to span an intron; the sense and anti-sense β-actin
primers were 5’-CGAGGCCCAGAGCAAGAG-3’ and 5’-
GACATAGCAGAGCTTCTCCTTGATG-3’.
The PCR cycle conditions were as follows: 94°C (30 s),
60°C (30 s), 72°C (1 min) for 35 cycles; 72°C (5 min). A
sample without cDNA template was used to verify that the
master mix was free from contaminants. PCR products were
electrophoresed on a 1.5% agarose gel and visualised under
UV light. The PCR products of equine UCN, CRHR1 and
CRHR2 were purified by using a GFX PCR DNA and Gel
Purification Kit (code 28-9034-70, GE Healthcare) and
sequenced.
Results
Immunoprecipitation and Western blot
The results of the immunoprecipitation and Western blot
analysis are shown in Fig. 1. Tissue extracts of the thyroid
gland of the horse reacted with the anti-UCN, -CRHR1 and –
CRHR2 antibodies.
Thyroid tissue extracts and the synthetic peptide UCN
reacted with the anti-UCN antibody (Fig. 1). The antibody
recognised one major protein band of approximately 16 kDa
from homogenates and one protein band of approximately
6.5 kDa from the synthetic peptide.
The thyroid tissue extracts also reacted with the anti-
CRHR1 and anti-CRHR2 antibodies (Fig. 1). The antibodies
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recognised one protein band measuring approximately
55 kDa. The thyroid tissue, in addition, did not react with
the anti-CRHBP antibody (Fig. 2). As a CRHBP-positive
control, we used horse adenohypophysis since CRHBP is
known to be highly expressed in this gland (Potter et al.
1992) in which it is located in adrenocorticotroph cells. In
addition, CRHBP antibody reacted with cerebellum, cerebral
cortex, thalamus and hypothalamus extracts. The antibody
recognised one protein band measuring approximately
37 kDa. Serum and liver did not react (Fig. 2).
Fig. 1 Expression of urocortin
(UCN), corticotropin-releasing
hormone (CRH) type 1 receptor
(CRHR1) and CRH type 2 re-
ceptor (CRHR2) by Western
blot (WB) in the horse thyroid
gland. Tissue extracts were
immunoprecipitated and immu-
noblotted with anti-UCN, -
CRHR1 and –CRHR2 antibod-
ies; UCN synthetic peptide
(100 ng/lane) and bovine adre-
nal medulla were used as posi-
tive controls. Beta-actin acted
as the input loading control of
immunoprecipitated proteins.
Molecular weight markers are
expressed in kDa
Fig. 2 CRH-binding protein
(CRHBP) expression by
Western blot (WB) and
immunohistochemistry in the
horse thyroid gland. CRHBP
immunoreactivity (-IR) was not
detected in tissue extracts of
thyroid gland, liver or horse
blood serum (top right) or in the
tissue sections of the thyroid
gland (b). In the positive
controls, CRHBP-IR was
detected in the tissue extracts of
the adenohypophysis (positive
control), various regions of the
brain (top left) and in the cells
of the adrenocorticotroph cells
(a). The blot was stripped and
incubated with anti-actin anti-
body as a loading control
(middle)
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Immunohistochemistry
In the horse thyroid gland, UCN-IR was found in the
follicular cells (Fig. 3a, d). CRHR2-IR was detected in
the C-cells (Fig. 3c, g). As shown by chromogranin A
immunohistochemistry, C-cells are larger than follicular cells
and have a large rounded nucleus. They usually do not extend
to the lumen of the follicles (Fig. 3f). Alternate CRHR2 and
chromogranin A antibody staining on serial 3-μm-thick sections
demonstrated a colocalisation of these two antigens in C-cells.
Fig. 3 Distribution of the UCN-, CRHR1- and CRHR2-immunoreactivities
in the horse thyroid gland. UCN-IR was distributed in thyroid
follicular cells (a). Higher magnification shows UCN-immunoreactive
epithelial cells (d). CRHR1-IR was located in the blood vessels (b).
Higher magnification of the thyroid blood vessel shows CRHR1-
immunoreactive cells in the vascular smooth muscle (e). CRHR2–IR
was distributed in the C-cells (c, g) as demonstrated by staining with
anti-chromogranin A antibody (as a marker of C-cells) of the previous 3-
μm-thick serial section (f). The double arrows indicate CRHR1-positive
vascular smooth muscle cells (arrowheads positive C-cells, FL follicular
lumen, L blood vessel lumen). Bar10 μm
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The distribution of CRHR1-IR was different from that for
UCN and CRHR2. CRHR1-IR was found only in the
smooth musculature of blood vessels (Fig. 3b, e).
CRHBP-IR was not detected in the horse thyroid gland
(Fig. 2b). In IR controls, CRBP-IR was detected in the cells
of the adrenocorticotroph cells (Fig. 2a).
RT-PCR analysis
RT-PCR experiments demonstrated that UCN, CRHR1 and
CRHR2 mRNAs were expressed in the thyroid gland, where-
as CRHBP mRNA was not expressed (Fig. 4). However,
CRHBP mRNA was expressed in the cerebellum, cerebral
cortex, hypothalamus, thalamus and adenohypophis (Fig. 4).
Discussion
The results of the present study revealed the presence of
UCN, CRHR1, CRHR2 mRNA and protein in the thyroid
gland of a mammalian species by using various experimen-
tal approaches. Specifically, immunoprecipitation and West-
ern blot analysis were used to study the presence of UCN
and its receptors. Immunohistochemical studies were per-
formed to evaluate the distribution and localisation of these
proteins, whereas RT-PCR experiments were performed to
reveal their mRNA. RT-PCR experiments revealed that
UCN, CRHR1 and CRHR2 mRNAs were expressed in the
horse thyroid gland, whereas CRHBP was not expressed,
confirming the immunohistochemical staining data.
Up until now, the expression of CRH-related peptides
has only been reported in the human thyroid gland under
pathological conditions. CRH, UCN 1 and UCN 3 have
been found to be expressed in cases of multiple endocrine
neoplasia type II accompanied by thyroid medullary carci-
noma and phaeochromocytomas (Kageyama et al. 2008). In
addition, CRH-IR has been detected in thyroid lesions,
predominantly in those related to autoimmune phenomena
(Scopa et al. 1994). Thyroid CRH might act as a proinflam-
matory cytokine during the inflammatory processes accom-
panying thyroid disorders.
In non-mammalian vertebrates, CRH appears to be a
potent stimulator of hypophyseal thyroid-stimulating hor-
mone (TSH) secretion and might therefore function as a
common regulator of both the thyroidal and adrenal/interre-
nal axes (De Groef et al. 2006; Kühn et al. 1998). CRH
exerts its dual hypophysiotropic action through two differ-
ent types of CRHRs (De Groef et al. 2003a, 2003b). Thyro-
tropes express type 2 CRHRs, while CRH-induced
corticotropin (ACTH) secretion is mediated by type 1
CRHRs on the corticotropic pituitary cells.
No data are available regarding the expression of UCN and
CRHR mRNAs in normal mammalian thyroid tissue. Previ-
ous studies have demonstrated the presence of a UCN-ergic
system under normal conditions in other endocrine glands, i.e.
adrenal gland (Squillacioti et al. 2011; Dermitzaki et al. 2007),
ovary (Muramatsu et al. 2001) and testis (Lee et al. 2011).
Immunoprecipitation and Western blot analysis have
shown that the anti-mammalian UCN antibody used in the
present study recognises a protein band with a molecular
weight of approximately 16 kDa in the horse thyroid gland.
This protein is comparable with the mammalian UCN pre-
cursor, which is a 122-amino-acid protein (Vaughan et al.
1995; Donaldson et al. 1996; Squillacioti et al. 2011). The
antibodies used against CRHR1 and CRHR2 recognise pro-
tein bands with molecular weights of approximately 55 kDa.
These proteins are comparable with the mammalian CRHRs
(Perrin et al. 2006; Chen et al. 1993). The antibody anti-
CRHBP does not recognise any protein bands in the horse
thyroid tissue or in the horse liver and serum, while recog-
nising a protein band in the adenohypophysis and various
brain regions. CRHBP has been found to be expressed in the
brain and pituitary gland of several mammalian species
(Potter et al. 1992; Baigent and Lowry 2000; Cortright et
al. 1995; Behan et al. 1996; Peto et al. 1999) and in human
blood serum (Orth and Mount 1987), whereas it has been
reported to be absent from rodent and equine serum (Potter
et al. 1991, 1992; Ellis et al. 1994). CRHBP is an important
modulator of CRH or UCN activity. In the absence of
CRHBP, CRH and other CRH-like ligands are no longer
bound, leading to increased CRH/UCN bioactivity. Our
results suggest that CRHBP in the horse plays a role in
antagonising the effects of CRH-related peptides in the brain
and pituitary gland but not in the thyroid gland.
The results of the present study have shown that, in the
horse thyroid gland, UCN-IR is present in the follicular
Fig. 4 UCN, CRHR1, CRHR2 and CRHBP expression as shown by
reverse transcription with the polymerase chain reaction in the horse
thyroid gland. UCN (177-bp fragment), CRH-R1 (200-bp fragment)
and CRH-R2 (230-bp fragment) were expressed in the horse thyroid;
β-actin (490-bp fragment) acted as a positive control. CRHBP (230-bp
fragment) was not expressed in the horse thyroid, whereas it was
expressed in the adenohypophysis, cerebellum, cerebral cortex, thala-
mus and hypothalamus (M molecular markers of 100-bp ladder)
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cells, whereas CRHR2-IR occurs in the C-cells. Thus, UCN
might affect calcitonin secretion via CRHR2 in a paracrine
manner. Additionally, other CRHR2 ligands, such as UCN2
and UCN3, probably interact with this receptor to regulate
C-cell activity.
C-cells are primarily known for producing calcitonin, a
hypocalcaemic and hypophosphataemic hormone. Neverthe-
less, in addition to their role in calcium homeostasis, C-cells
might be involved in the intrathyroidal regulation of follicular
cells, further suggesting a possible interrelationship between
the two endocrine populations. C-cells produce and secrete a
number of different regulatory peptides. Some of these regu-
latory peptides display an inhibiting action on thyroid hor-
mone secretion, such as calcitonin, calcitonin gene-related
peptide and somatostatin (Ahren 1989, 1991; Zerek-Melen
et al. 1989), whereas others act as local stimulators of thyroid
hormone synthesis, such as gastrin-releasing peptide, heloder-
min and serotonin (Ahren 1989; Grunditz et al. 1989; Tamir et
al. 1992). Despite the receptors for some of the above men-
tioned substances, e.g. somatostatin or serotonin, being
expressed by follicular cells (Tamir et al. 1992, 1996; Ain et
al. 1997), a clear role has not yet been assigned to these C-cell-
secreted regulatory factors.
Furthermore, ghrelin and thyrotropin-releasing hor-
mone, the two additional regulatory peptides that orches-
trate the hypothalamic control of the thyroid function
through thyrotropin, are also expressed in C-cells (Gkonos
et al. 1989; Korbonits et al. 2001; Raghay et al. 2006).
Rat and human C-cell lines express the thyrotropin recep-
tor at both mRNA and protein levels. These results con-
firm that C-cells, under the regulation by thyrotropin, are
involved in the hypothalamic-pituitary-thyroid axis and
suggest a putative role in the local fine-tuning of follicular
cell activity (Morillo-Bernal et al. 2009).
Recently, additional evidence has been presented that a
functional interaction between follicular and C-cells medi-
ated by the release of the peptidergic hormones or neuro-
petides does indeed exist (Morillo-Bernal et al. 2009, 2011).
As far as we know, no data concerning the regulation of C-
cells by follicular cells have been published. However, this
kind of intrathyroidal regulation has recently been postulated,
as evidence has become available that follicular and C-cells
evolve with the same rhythm during the hyperstimulation or
suppression of thyroid function (Martín-Lacave et al. 2009).
We have found CRHR1-IR in the vascular smooth mus-
culature, thus suggesting a role for UCN in modulating the
blood flow of the thyroid gland. This hypothesis is corrob-
orated by the finding that UCN is a dilator of rat (Abdelrahman
et al. 2005; Lubomirov et al. 2001) and mouse (Lubomirov et
al. 2006) arteries.
Thyroid blood flow together with thyrotropin (TSH) reg-
ulates the uptake of iodide by the thyroid gland (Arntzenius
et al. 1991; Ingbar et al. 1986). Iodide is an essential element
for the production of thyroid hormones. Alterations in the
thyroidal uptake of iodide can cause changes in the produc-
tion of thyroid hormones and the regulation of iodide uptake
is important for thyroid gland activity.
In conclusion, these results suggest that UCN, CRHR1
and CRHR2 are expressed in the horse thyroid gland and
that a local regulatory system of thyroid functions based on
UCN and CRHRs exists. UCN plays a role in the regulation
of the blood flow of this gland via CRHR1 and of calcitonin
synthesis via CRHR2. In addition, the bioavailability of the
UCN in this system is not modulated by CRHBP, because
this protein is not expressed in the horse thyroid gland.
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